Introduction
Cirrhosis is the common endpoint of various aetiologies of liver injury and represents the severest histological stage. For decades cirrhosis has been considered to signal an invariably dismal prognosis and equated with end stage liver disease. However, it is becoming increasingly apparent that cirrhosis is not a single disease stage, and that prognosis is highly variable, with one-year mortality ranging from 1 to 57% [1] . Therefore, compensated and decompensated cirrhosis has been further sub-classified into several clinical prognostic stages, with distinct differences in mortality between them [2] [3] [4] .
In traditional qualitative histological systems, cirrhosis [5] is the last histological stage and therefore these cannot be used to address the increasing need of further prognostication. More recently, histological systems of sub-classifying cirrhosis have been used, mainly based on semi-quantitative evaluation of nodular size and septal width. These include proposals by Laennec based on the original histological description of cirrhosis [6] [7] [8] , by Nagula [9] and Kumar [10] ; all have used hepatic vein pressure gradient (HVPG) as a surrogate endpoint in parallel with Laennec's system. A purely quantitative assessment of nodules and septa was recently described, which correlated well with HVPG [11] . Our group developed a quantitative method of measuring fibrous tissue, using digital image analysis of the proportion of collagen in liver tissue, namely collagen proportionate area (CPA) [12] . This method has been validated both against HVPG and clinical outcomes [12] [13] [14] [15] .
In the present study, we compared the performance of all histological semi-quantitative and quantitative methods specifically developed and described to date, for sub-classifying cirrhosis with CPA, to evaluate how well they could distinguish patients with and without hepatic clinical decompensation at presentation, and in predicting future decompensating events.
biopsies P10 mm in length. We collected baseline characteristics, including demographic and laboratory parameters and documented episodes of decompensation prior or at the time of the liver biopsy. Patients' follow-up data were collected until their first episode of clinical decompensation or until December 2012. Decompensation was defined as any episode of variceal bleeding, clinically detectable ascites, encephalopathy or non-obstructive jaundice. We censored patients at the time of a liver transplant, development of HCC, date of sustained virological response (SVR) if treated for HCV, date of undetectable viral load if treated for HBV, and at 6 months of complete abstinence in cases of alcoholrelated cirrhosis. Patients with cirrhosis after liver transplantation were excluded.
Liver biopsy samples
Liver biopsies were performed either transjugularly with a 19G TruCut needle [14] or percutaneously with a 16G Menghini needle.
Liver biopsy samples were formalin-fixed, paraffin-embedded and routinely stained with hematoxylin and eosin (H&E), DPAS (PAS stain with diastase digestion), orcein, Victoria Blue and Perl's. Another section of tissue was stained with picro-Sirius red for collagen quantification and determination of CPA by digital image analysis (DIA). Two pathologists (TVL and SB), blinded to clinical data, independently evaluated all biopsies and performed the semi-quantitative analyses. Where there was disagreement in the scoring of any sample, the sections were re-assessed by both pathologists together and a consensus reached. A single operator (SB) performed the quantitative nodule and septal width measurements. CPA measurements were performed by AH.
Histological sub-classification
The Laennec [6, 7] , Kumar [10] , Nagula [9] , and Sethasine [11] sub-classification were performed as previously described (see Supplementary Materials and methods for details).
Collagen proportionate area using digital image analysis (DIA)
This method is described in detail elsewhere [12, 16] . In summary, the Sirius Red stained biopsy sections were used for DIA. The equipment used was a digital camera (Canon Powershot A640 attached to a close-up copy-stand with backlighting) connected to a compatible personal computer. Calibration of the camera was: 154 Â 154 pixels = 23,716 = 1 mm 2 . After whole section digital image capture, CPA was measured with Zeiss KS300 image analysis software. A RGB (Red, Green, Blue) threshold was then used to detect areas of stained collagen and the collagen mask was calculated as an area in pixels. A ratio (CPA) is expressed as a percentage. Tissue within 5 mm of the capsule and large blood vessels were avoided. The CPA measurement includes a manual editing step to eliminate image artifacts, and operator dependent thresholding to determine the stained area of the section.
Statistical analysis
All data were analysed using the statistical package SPSS (version 21.0, IBM). Statistical analysis was performed using t test, ANOVA, Mann-Whitney or KruskalWallis tests for comparisons of continuous variables between or among groups, corrected Chi squared method or two-tailed Fisher's exact test for comparisons of qualitative data and Spearman's co-efficient for correlations of quantitative data, when appropriate. Multivariate and survival analyses were performed using logistic regression and Cox regression models respectively. Only variables with p values 60.10 at univariate analysis were entered in the multivariate analysis models. A two-tailed p value <0.05 was considered statistically significant.
Results

Patient flow
A total of 159 patients had histological cirrhosis diagnosed [5] between 2003 and 2007. We excluded the following: 16 because the histological diagnosis was of incomplete cirrhosis, 41 because biopsy samples were too short (length <10 mm) and 22 because the biopsies were too fragmented (>4-5 fragments). Exclusion was not because biopsies were suboptimal for the diagnosis of cirrhosis. The too short or fragmented samples were excluded, as a minimum measurement of 5 nodules required by Sethasine's method was not feasible, while with fragmentation fibrous septa are often missed, thus measurement is not possible. CPA can be reliably performed in fragmented samples of adequate length, but not in too short samples [16] . A further 11 post transplant cases were excluded, leaving 69 patients as the study population.
Patient characteristics
Mean age was 52.3 ± 11 years. Alcohol was the main aetiology (38%) followed by hepatitis C (27.5%). Mean MELD score was 11.8 ± 5.8 (median 10); the distribution across Child classes was: A (63.8%), B (18.8%), and C (17.4%). At the time of the biopsy, 24 patients (34.8%) had had a previous episode of clinical decompensation; of the 45 patients who were compensated, 11 (24%) had at least one episode of clinical decompensation during a median follow up of 56 months. All patient characteristics are summarized in Table 1 .
Histological characteristics
Forty-two patients had a transjugular liver biopsy (TJLB) and the rest a percutaneous one (PLB). The mean biopsy length was 21.6 ± 8.2 mm (range 10-46.3), with TJLB samples being significantly longer (TJLB vs. PLB 23.9 ± 8.9 vs. 18 ± 5.4 mm, p = 0.003). The median TJLB width was 0.65 mm (range 0.5-0.7), whereas the median PLB width was 1.18 mm (range 1.0-1.5). The median number of nodules/biopsy was 15. The distribution according to Laennec classification was 5.8%, 44.9%, and 49.3% in classes 4a, 4b, and 4c respectively. The median nodule size across different B (63, 91%). Only 2 patients (2.9%) had small cirrhotic nodules, 66 (95.7%) had mixed sizes and 1 (1.4%) had large nodules according to the Nagula classification. Septa were thin in 5 patients (7.2%), medium in 36 (52.2%) and thick in 28 (40.6%) according to the same classification. Mean CPA was 23 ± 12.4. All the above is summarized in Table 2 .
CPA correlation with other histological parameters CPA increased significantly across the Laennec scoring system, with mean values in stages 4a vs. 4b vs. 4c of 9.1 ± 5.2, 15.8 ± 6.3, and 31.3 ± 11.5 respectively (p <0.001). This difference was also present in the Kumar classification, with CPA in class A vs. B being 8.7 ± 4.7 vs. 24.4 ± 12.1 (p = 0.003). CPA also increased as septal thickness increased, with values of 9.2 ± 4.5, 17.7 ± 7.8 and 32.4 ± 11.8 in thin, medium and thick septa respectively (p <0.001). The difference was less pronounced as nodule size increased, probably due to the small number of patients with small nodules (mean values in small and mixed were 36.4 ± 7.1, 22.9 ± 12.2 respectively, p = 0.069, only one patient with large nodules). The above is shown in Fig. 1 . CPA significantly and positively correlated with septal width (r = 0.622, p <0.001) and negatively with size of nodules (r = À0.620, p <0.001), while there was no correlation with number of nodules or nodules/mm of tissue (p = n.s.).
Time required for histological analysis
Histological sub-classification using semi-quantitative methodology required an average of 5 min/sample. CPA analysis, including the manual editing of removing the structural collagen from the measurement area, required an average of 10 min/sample. Quantitative measurement of septal thickness and nodule size required 20-30 min/sample depending on the number of nodules, which is compatible with the timing in the original publication (Garcia-Tsao, personal communication). All the above represent the average time spent per operator after the initial training period.
Predictors of decompensation at the time of biopsy
All histological parameters were tested as potential predictors of clinical decompensation up to the time of biopsy. Laennec stage was associated with decompensation (decompensation in 4a vs. 4b vs. 4c was 0% vs. 12.9% vs. 59%, p <0.001), while Kumar stage was only marginally associated (decompensation in A vs. B was 0/6 vs. 24/63, p = 0.085). Patients with thick or medium septa were more likely to be decompensated, than patients with thin septa (61% vs. 19% vs. 0% respectively, p = 0.001), while there was no significant association of decompensation with the predominant size of nodules (decompensation in small vs. mixed vs. large was 100% (2/2) vs. 33% (22/66) vs. 0% (0/1), p = n.s.). Quantitative septal width (p = 0.020), nodule size (p <0.001), and CPA (16.9 ± 7.5 vs. 34.5 ± 11.6, p <0.001) were significantly associated with decompensation. Finally, patients with decompensation had significantly higher MELD score than patients without (17.4 ± 6.1 vs. 8.9 ± 2.6, p <0.001).
In the multivariate analysis, we entered CPA separately with each proposed sub-classification systems of cirrhosis of Laennec [6, 7] and Kumar [10] , with septal thickness and nodule size (Nagula classification) [9] , and with quantitative septal width and nodule size (Sethasine et al.) [11] , and therefore evaluated four different models. In all cases, CPA was the only variable independently associated with clinical decompensation up to the time of biopsy, with an odds ratio that ranged from 1.245 to 1.292 (Table 3) . We finally entered both CPA and MELD in the multivariate model, and both emerged as independent predictors of the presence of baseline decompensation ( Table 3) .
The AUROC of CPA alone to predict baseline clinical decompensation was 0.909, and a cut-off of 25.5 had a sensitivity of 0.875 and a specificity of 0.889. Comparative AUROCs are shown in Fig. 2 .
Future decompensating events
Mean follow-up was 59 ± 38 (median 65) months, during which, 11/45 (24%) patients compensated at baseline developed a decompensating event (3 were transplanted and 2 died). Most had ascites as the first decompensation event (8/11, 73%). In Cox regression analysis, the Laennec, Kumar and Nagula semiquantitative sub-classification parameters and also the quantitatively measured septal thickness and nodular size were not associated with future decompensation. The previously published cut-off of 169.01 lm for septal width [17] was not associated with future decompensation. Amongst histological parameters, only CPA was significantly associated with future decompensation (OR: 1.117, 95% CI 1.020-1.223; p = 0.017).
Discussion
In the present study, we showed that of all the histological methods used to date, to sub-classify cirrhosis [6] [7] [8] [9] [10] [11] , CPA independently and most strongly predicts both decompensation at baseline and most importantly future clinical decompensating events. Whereas other published studies explored one method at a time, we were able to compare all published methods in the same patient cohort using the hard endpoint of clinical outcomes. Sub-classification of cirrhosis is becoming an increasing clinical need, as new approaches and strategies to prevent and delay patients from progressing to decompensation are emerging [18, 19] . MELD and UKELD scores are used for deciding on when to transplant patients, however they are applicable only very late in the disease process and cannot be used for prognosis in the early stages of cirrhosis. Non-invasive tests have recently been shown to predict clinical decompensation in patients with advanced fibrosis or early cirrhosis [20] . Ideally, the predictive ability of these tools should be compared to semi-quantitative or quantitative histological methods of sub-classification of cirrhosis [21] .
Histological semi-quantitative methods of sub-classification represent a more detailed way of further sub-classifying the previously termed micro-and macronodular cirrhosis. Amongst the semi-quantitative methods described, the Laennec classification, with three sub-categories, has been studied in the greatest number of patients with various aetiologies of liver disease, and correlated both with portal hypertension as assessed by HVPG [6, 8] and liver related clinical outcomes [7] . The classification proposed by Nagula independently assessed septal width and nodule size, which was predictive of clinically significant portal hypertension in 43 patients with various aetiologies of cirrhosis [9] . Kumar et al. used a variant of the Nagula classification, with two sub-categories that correlated with clinically significant portal hypertension in 47 patients with HBV cirrhosis [10] .
Although semi-quantitative sub-classification is fairly simple and quick, and does not need specialized equipment, it is still a crude tool for sub-classifying cirrhosis and offers no more than two or three further stages. Indeed, there is significant overlap in HVPG values among patients with Laennec stages 4a and 4b [6] , and amongst those with thin and medium septa or large and mixed nodules [9, 10] . Furthermore the Laennec sub-classification system and similar semi-quantitative histological methods have an evaluation bias represented by the width of the biopsy, as all are based on a subjective evaluation of the nodule size and septal thickness in relation to the biopsy width, without a precise and rigorous definition of nodule size and septal thickness. Kim [6] , Kumar [10] , and Rastogi [8] described that only liver biopsies with a width of >1.2 mm were included in their studies. The cut-off of biopsy width >1.2 mm is arbitrary and if this value is adopted in routine practice it would exclude many PLBs and all TJLBs from the assessment. Percutaneous liver biopsy with a 15G Menghini needle has an average width of 0.75 mm in fixed tissue as Menghini described in his original paper [22] . Transjugular liver biopsies using a 19G Tru-cut needle have a histological median width of 0.6 mm (range 0.4-0.8) [16, 22] . In the current study the median TJLB width was 0.65 mm (range 0.5-0.7); whereas the median PLB width was 1.18 mm (range 1.0-1.5). Nowadays patients with more advanced cirrhosis are more likely to have a transjugular rather than a percutaneous biopsy.
There were 8 TJLBs (12%) classified as Laennec 4c because there was a ''very broad septum'' (defined as the region of extinction wider than 1 biopsy width). As the median width of the PLBs was greater than TLJBs (median 0.65 vs. 1.18 mm), if these 8 cases had been PLBs, they could have been subcategorised as Laennec 4b (Fig. 3) . Similarly as the size of a nodule was defined in relation to biopsy width, a nodule measured between 0.65 mm and 1.18 mm, could have been defined as ''small nodule'' in a PLB and ''large nodule'' in a TJLB.
More recently, a purely quantitative method of sub-classifying cirrhosis has been described, that takes into account fibrosis area, septal width and nodule size [11] . The authors themselves acknowledged that their method is cumbersome and less accurate than the ''bird's eye'' view for the assessment of nodules and septa [11] . We were able to reproduce this method for septal width and nodule size assessment, confirming that the method is not time-effective for routine practice. Furthermore, we agree with the authors that the quantification of median nodule size and median septal width can average different sizes and may over-represent a non-predominant type of nodule. In our study, although >3 mm nodules were measured, this finding was not apparent in the presentation of the final data (Table 2) , because the median nodule size value ''discounted'' the outlying values. A further problem is that fibrosis area is still not validated against clinical outcomes, has been only used in a limited number of patients and has provided contradictory results even when analyzing the same patient cohort [11, 17] . A recent publication using fibrosis area was also inconclusive, as it did not evaluate its predictive value in multivariate analysis [8] .
We used CPA instead of fibrosis area for quantifying fibrosis. CPA compared to fibrosis area has an additional manual step of editing structural collagen and therefore offers increased accuracy in calculating the parenchymal fibrous tissue collagen [12] . Our analysis revealed that CPA increased proportionately across all stages of cirrhosis using the semi-quantitative sub-classification systems described, and more importantly, that it was the only independent histological predictor of clinical decompensation. This was not unexpected, as thicker cirrhotic septa contain more collagen. Moreover, it added to MELD in the diagnosis of decompensation up to the time of biopsy and thus provided additional prognostic information. Finally, despite the limited number of patients who were compensated at baseline and the small number of decompensating events at follow up, CPA was the only histological variable significantly associated with the development of such events. Therefore, our results provide a proof of concept that measurement of CPA is currently the best method for accurate sub-classification of cirrhosis. This is also illustrated in Fig. 4 .
Currently, CPA is a well-validated method of fibrosis quantification that has been assessed in cirrhotic and non-cirrhotic cohorts and in pre-and post-transplant populations and, more importantly, has been validated against liver-related clinical outcomes [12] [13] [14] [15] 23] . Additional work has shown that fibrosis distribution is not statistically different across liver lobes in cirrhosis [24] and that the sample required to assess CPA is not larger than that of the standard liver biopsy [16] . It is a fairly quick procedure, requiring approximately 10 min, and has excellent reproducibility with concordance coefficients between intra-and inter-observer evaluation of 0.98 and 0.97 respectively [12] . Thus it overcomes traditional liver biopsy shortcomings and is more accurate than using the Laennec system, which has an interobserver agreement of 0.83 [6] . Although it requires the purchase of specialized software and equipment with a one-off cost of £6500, it could be argued that given the prognostic and therapeutic implications, quantitative determination of fibrosis (CPA) should be routinely measured in tertiary liver centers.
Our study included patients with various aetiologies of liver disease and as mentioned the quantity of fibrosis differs among different aetiologies [24] . Therefore, CPA might prove an even more accurate predictor of clinical outcomes in cohorts with single liver disease aetiologies with determination of aetiology-specific thresholds. This consideration also applies to non-invasive markers (NITs) such as transient elastography [25] and is an area where further work needs to be done. A comparison of CPA and NITs is needed with respect to clinical outcomes. In our cohort, only few patients where categorized in Kumar stage A, Laennec 4a or had thin nodules according to the Nagula system. This might indeed be an under-representation of lower grades of histological sub-classification in this cohort or, more probably, highlights a somewhat limited reproducibility of such systems even amongst experienced pathologists in tertiary centers, further reinforcing the need of an accurate and reproducible quantitative system of sub-classifying cirrhosis. In our study population CPA measurement was only feasible in 75% of patients due to inadequate sample size. This percentage can be improved if TJLB are preferentially used over PLB, as multiple passes can guarantee adequate sample size [26] . Conversely, transient elastography is not feasible in 18% of patients and also in patients with ascites, therefore in Child-Pugh B and above [27] . Serum NITs are feasible in >95% of patients.
In conclusion, we have shown that cirrhosis can be accurately sub-classified using quantification of fibrosis with CPA in liver biopsy samples P10 mm in length and furthermore that CPA is the only independent predictor of clinical decompensation amongst all other histological sub-classification systems described to date. Our new understanding of the natural history, prognosis and prevention of complications in cirrhosis requires that accurate tools of sub-classification are developed, validated and used in routine clinical practice and CPA already fulfills the first two essential steps. Finally, future work should also evaluate a comparison of non-invasive markers with quantitative histological parameters against clinical outcomes in patients with advanced fibrosis, so that the validity and accuracy of all available tools can be fully assessed. In both, there were mixed, variably sized nodules and variable septal width with at least one very broad septum and predominant medium to thick type of septae. Although the two biopsies could look different, both biopsies had same Laennec stage cirrhosis (4c), same Kumar stage B and same Nagula's mixed nodules. Nagula's septum was medium in (A) and thick in (B). In (A), the median nodule size according to Sethasine's method was 270.12 lm and median septal width was 120.05 lm; whilst in (B), the median nodule size was 250.30 lm and median septal width was 180.60 lm, despite the presence of large nodules in (A) (largest nodule in (A) was 3020.30 lm and in (B) was 940.70 lm) and thick fibrous septa in (B) (widest septum in (A) was 210.25 lm and in (B) was 960.80 lm), as the median value discounted the outlying figures. Only collagen proportionate area (CPA) was able to clearly demonstrate the difference between the two biopsies: 21.6% in A and 46% in B. (This figure appears in colour on the web.)
